Inavolisib | CAS No. 2060571-02-8

Inavolisib

Basic Information

View in Editor

CAS Number

2060571-02-8

Molecular Formula

C18H19F2N5O4

Molecular Weight

407.37 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Ethers

Basic Chemical Raw Materials Organic Chemicals Amines

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Dyes and Pigments Organic Dyes

Fine Chemicals Surfactants Anionic Surfactants

Fine Chemicals Specialty Chemicals UV Stabilizers

Agricultural Chemicals Pesticides Herbicides

Laboratory Chemicals Research Chemicals Biochemical Reagents

Basic Physical Properties

SMILES

View in Editor

NC(=O)[C@@H](Nc1ccc2c(c1)OCCn1c2nc(c1)N1C(=O)OC[C@H]1C(F)F)C

InChI

InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1

InChIKey

SGEUNORSOZVTOL-CABZTGNLSA-N

LogP

1.8184999999999993

Topological Polar Surface Area

111.71 Å²

Hydrogen Bond Donor/Acceptor

3 / 9

Complexity

641

Synonyms & References

English

GDC-0077
GDC0077
Inavolisib
RG6114
L4C1UY2NYH
Ro7113755
(S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide
Inavolisib [USAN]
GTPL9636
BDBM295665
AMY16810
NSC800729
US10112932, Compound 101
WHO 11204
DB15275
(2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]be

MDL Number

MFCD31382124

FAQ

What regulatory guidelines apply to Inavolisib (CAS: 2060571-02-8)?

Inavolisib (CAS: 2060571-02-8) is subject to regulatory guidelines under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH in the European Union, and FDA/EPA requirements for the import, manufacture, and sale of chemical substances in the US and EU. Detailed information on storage, handling, and disposal should be obtained from the respective regulatory bodies.

Are there alternatives to Inavolisib (CAS: 2060571-02-8) in synthesis?

Inavolisib (CAS: 2060571-02-8) can be synthesized using alternative methods and reagents. Common alternatives include using related phosphoinositide 3-kinase inhibitors, which may offer similar functionalities. However, the choice of alternative will depend on the specific synthesis requirements and desired chemical properties.

What is the market or research trend for Inavolisib (CAS: 2060571-02-8)?

The market for Inavolisib (CAS: 2060571-02-8) is driven by ongoing research and development in oncology. Recent trends indicate increasing interest in developing targeted therapies for cancer, and Inavolisib is part of this growing field. Additionally, price trends and demand for this compound are closely tied to advancements in drug development and clinical trials.

How should waste containing Inavolisib (CAS: 2060571-02-8) be handled?

Waste containing Inavolisib (CAS: 2060571-02-8) should be collected and disposed of in accordance with local and national regulations. Incineration or professional waste disposal services are recommended. Proper handling and disposal require the use of appropriate personal protective equipment and adherence to environmental protection precautions to minimize the risk of exposure and environmental contamination.